Metastatic Melanoma Clinical Trial Pipeline Analysis Featuring 75+ Key Companies by DelveInsight

By Laura Campbell On Nov 24, 2022

DelveInsight’s, “Metastatic Melanoma Pipeline Insight, 2022” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Metastatic Melanoma Pipeline Report

DelveInsight’s Metastatic Melanoma pipeline report depicts a robust space with 75+ active players working to develop 75 + pipeline therapies for Metastatic Melanoma treatment.
Leading Metastatic Melanoma companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, and others are developing new drugs for metastatic melanoma to improve the treatment landscape.
Key Metastatic Nelanoma pipeline therapies in various stages of development include EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, HBI-8000, NKTR-214,CMP-001, IO102-IO103, EVX-01, APX005M, BCD-217, Dostarlimab, LXH254, Niraparib, BNT111, UV1, YH003, Retifanlimab, L19IL2+L19TNF, Pexa-Vec, APG-115, Cabozantinib, RO7247669, PV-10, BGB324, VB10.NEO, IMO-2125, ABI-007, HX008, BVD-523, IOV-4001, ST101, BGB-10188, DYP688, ATL001, PAC-1, IN10018, SX-682, TILT-123, PV-001-DC, CDX-301, TBX-3400, GR-MD-02, FHD-286, SD-101, MB-CART20.1, BMS-986249, SEA-CD40, LAG525, Fianlimab, ADP-TILIL7, Poke-101, and others.
In the Metastatic Melanoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Melanoma.

Recent Developmental Activities in the Metastatic Melanoma Pipeline

EVX-01, is a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.
IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.
AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.

Request a sample and discover the recent advances in Metastatic Melanoma Treatment Drugs @ Metastatic Melanoma Clinical Trial Outlook

Metastatic Melanoma Overview

Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. Metastatic melanoma is a disease that occurs when the cancerous cells from the original tumor (primary tumor) get loose, spread by traveling through the lymph or blood circulation, and start a new tumor (metastatic tumor) somewhere else. Once it spreads, or metastasizes, the disease is known as metastatic melanoma. This type of melanoma may typically occur during stage 3 or stage 4. Common melanoma metastasis sites include the lymph nodes, lungs, liver, bones and brain. Metastatic melanoma symptoms and signs may include: Fatigue, swollen or painful lymph nodes, weight loss, loss of appetite, trouble breathing or a cough that doesn’t go away, bone pain, headaches, seizures, swelling of the liver.

Metastatic Melanoma Emerging Drugs

EVX 01: Evaxion Biotech
IN 10018: InxMed
AV MEL 1: AiVita Biomedical

Metastatic Melanoma Pipeline Therapeutic Analysis

There are approx. 75+ key companies which are developing the therapies for Metastatic Melanoma. The companies which have their Metastatic Melanoma drug candidates in the most advanced stage, i.e. Phase II, Evaxion Biotech.

Metastatic Melanoma Pipeline Therapies and Key Companies

HBI-8000: HUYABIO International, LLC
IO102-IO103: IO Biotech
CMP-001: Checkmate Pharmaceuticals
EVX-01: Evaxion Biosciences
APX005M: Apexigen, Inc.
BCD-217: Biocad
Pixatimod: Zucero Therapeutics
Selinexor: Karyopharm Therapeutics
Relatlimab: Bristol-Myers Squibb
V937: Viralytics
NEO: Nykode Therapeutics

Learn more about the novel and emerging metastatic melanoma pipeline therapies @ Metastatic Melanoma Clinical Trials

Metastatic Melanoma Pipeline Therapeutic Assessment

By Product Type
By Stage
By Route of Administration
By Molecule Type

Scope of the Metastatic Melanoma Pipeline Report

Coverage- Global
Key Metastatic Melanoma Companies: Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC., IO Biotech, Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline, Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, and others
Key Metastatic Melanoma Pipeline Therapies: EVX 01, IN 10018, AV MEL 1, Lifileucel, V937, NEO-PTC-01, Relatlimab, CyPep-1, HBI-8000, NKTR-214, CMP-001, IO102-IO103, EVX-01, APX005M, BCD-217, Dostarlimab, LXH254, Niraparib, BNT111, UV1, YH003, Retifanlimab, L19IL2+L19TNF, Pexa-Vec, APG-115, Cabozantinib, RO7247669, PV-10, BGB324, VB10.NEO, IMO-2125, ABI-007, HX008, BVD-523, IOV-4001, ST101, BGB-10188, DYP688, ATL001, PAC-1, IN10018, SX-682, TILT-123, PV-001-DC, CDX-301, TBX-3400, GR-MD-02, FHD-286, SD-101, MB-CART20.1, BMS-986249, SEA-CD40, LAG525, Fianlimab, ADP-TILIL7, Poke-101, and others.
Metastatic Melanoma Key Companies
Metastatic Melanoma Key Products
Metastatic Melanoma- Unmet Needs

Table of Content

Introduction
Metastatic Melanoma Executive Summary
Metastatic Melanoma: Overview
Metastatic Melanoma Pipeline Therapeutics
Metastatic Melanoma Therapeutic Assessment
Metastatic Melanoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name : Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
EVX 01: Evaxion Biotech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
IN 10018: InxMed
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Metastatic Melanoma Key Companies
Metastatic Melanoma Key Products
Metastatic Melanoma- Unmet Needs
Metastatic Melanoma- Market Drivers and Barriers
Metastatic Melanoma- Future Perspectives and Conclusion
Metastatic Melanoma Analyst Views
Metastatic Melanoma Key Companies
Appendix

For further information on the metastatic melanoma pipeline therapeutics, reach out to New Drugs for Metastatic Melanoma Treatment

About Us

Contact Us

Yash Bhardwaj

Published Wed, 23 Nov 2022 23:04:18 -0600